Events
BIOCOM 2021
Geoff Nosrati, Ph.D., ImmunoScape’s Chief Business Officer, will be presenting on, “Advancing the development of next-generation therapeutics with the Deep Immunomics platform.” at Biocom’s upcoming Global Life Science Partnering Conference.
Session date: February 25th, 2021
Session time: 10:00-10:14am PST
World Vaccine & Immunotherapy 2020
Please join our oral presentation on, “Broad and Prevalent SARS-CoV-2 CD8+ T Cell Response in Recovered COVID-19 Individuals Demonstrates Kinetics of Early Differentiation” and meet our team.
Session Date: Tuesday, December 1, 2020
Session Time: 4:20 PM PST
Come visit ImmunoScape’s virtual booth at the WVIC 2020, December 1-3, 2020 and chat with us.
In this study, using our multiplexed peptide-MHC tetramer approach to screen 408 SARS-CoV-2 candidate epitopes for CD8+ T cell recognition, we identified 52 unique epitope hits (18 unreported), spanning different viral proteins. Insights gained from these SARS-CoV-2 reactivities and their associated T cell profiles capable of differentiating into long-term mediators of protection may guide the rational design of COVID-19 vaccine candidates to curb this pandemic.
IDWeek 2020™
October 21-25, 2020
Please join our oral presentation on, “Broad and Prevalent SARS-CoV-2 CD8+ T Cell Response in Recovered COVID-19 Individuals Demonstrates Kinetics of Early Differentiation” and meet our team!
Session Date: Saturday October 24, 2020
Session Time: 1:15 PM – 3:00 PM
Come visit ImmunoScape’s virtual booth at the IDWeek 2020™ and chat with us!
In this study, using our multiplexed peptide-MHC tetramer approach to screen 408 SARS-CoV-2 candidate epitopes for CD8+ T cell recognition, we identified 52 unique epitope hits (18 unreported), spanning different viral proteins. Insights gained from these SARS-CoV-2 reactivities and their associated T cell profiles capable of differentiating into long-term mediators of protection may guide the rational design of COVID-19 vaccine candidates to curb this pandemic.
The Digital International Liver Conference™ 2020
August 27-29, 2020
Virtual event
ImmunoScape and Gilead Sciences recently presented findings at the Digital International Liver Congress 2020 that demonstrated the feasibility of simultaneously identifying and deeply characterizing rare HBV-specific T cells in heterogeneous HBV patient cohorts to facilitate the development of more effective therapeutic strategies for hepatitis B virus (HBV) infection.
BIO Digital
June 8-12, 2020
New Virtual Event
When collaboration is more vital than ever, you can still rely on BIO to bring the industry together. For 2020, the BIO International Convention will transition to a new, virtual event format, BIO Digital. This virtual gathering of the global biotech industry provides access to key partners via BIO One-on-One Partnering, educational resources to help drive your business, and the insights you need to continue critical research and development. We may not be able to gather in person, but nothing stops innovation.
ASCO20 Virtual Scientific Program
May 29-31, 2020
New Virtual Event
ASCO will deliver the latest cancer science to the global community in this year’s ASCO20 Virtual Scientific Program. The program will feature over 250 oral abstract presentations and 2,500 poster presentations in 24 disease-based and specialty tracks.Content will be delivered in two formats – on-demand and scheduled broadcasts. The on-demand content will be available starting on Friday, May 29, and will include posters and scientific sessions not covered in the scheduled broadcast. Sessions will be broadcast on May 30-31 from 9:30am – 5:00pm ET.
Click here to learn more about this conference.
AACR Annual Meeting 2020 | Turning Science into Lifesaving Care
April 24-29, 2020
San Diego Convention Center
San Diego, CA
The AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer research—from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy—and highlights the work of the best minds in research and medicine from institutions all over the world.
Click here to learn more about this conference.
Advances in Cancer Immunotherapy | Keystone Symposia
March 22-26, 2020
Fairmont Chateau Whistler
Whistler, BC Canada
Visit our poster number 1001 on Monday, March 23, 2020 at Poster Session 1
Immuno-phenotyping of tumor-specific CD8 T cells using high-dimensional mass cytometry.
Cancer immunotherapy is providing an unprecedented level of long-term antitumor activity in some patients, but unfortunately the majority of patients still do not experience sustained clinical benefit. Many questions remain unanswered. The conference program will include sessions which cover topics such as new analysis techniques, methodologies, and how to integrate high throughput data to provide a more comprehensive understanding of cancer and the immune system.
Click here to learn more about this conference.
Molecular Med TRI-CON | Advancing Precision Medicine
March 1-4, 2020
Moscone South Convention Center
San Francisco, CA
Visit our poster on March 2-3 – Poster #36
Immuno-phenotyping of tumor-specific CD8 T cells using high-dimensional mass cytometry.
The Molecular Medicine Tri-Conference will showcase new technologies to advance precision medicine along with emerging
therapeutics across a spectrum of applications. Key opinion leaders will discuss the latest tools, clinical advances, and commercial applications of a broad range of new and diverse products for vast improvements in medicine and healthcare.
Click here to learn more about this conference.
Get a chance to meet Dr. Evan Newell at SNO Think Tank Meeting on “Immunotherapy in Neuro-Oncology: Promises and Challenges”
2019 SNO Annual Meeting
Innovation to Overcome Tumor Resistance
Wed., Nov. 20 (Pre-Meeting)
Thursday, Nov. 21 (Education Day)
Friday, Nov. 22 – Nov. 24 (Main Meeting)
This meeting will be held Wednesday, November 20, 2019, at the Marriott Desert Ridge Hotel in Phoenix, Arizona, immediately preceding the SNO Annual Meeting.
Dr. Evan Newell will be speaking on the topic: Profiling of tumor-specific vs bystander tumor-infiltrating T cells
Click here for more information.